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Background: Recently, stem cells have been considered for the treatment of heart diseases, but no marked improvement 
has been recorded. This is the first study to examine the functional and histological effects of the transplantation of human 
amniotic mesenchymal stromal cells (hAMSCs) in rats with heart failure (HF).
Methods: This study was conducted in the years 2014 and 2015. 35 male Wistar rats were randomly assigned into 5 equal 
experimental groups (7 rats each) as 1- Control 2- Heart Failure (HF) 3- Sham 4- Culture media 5- Stem Cell Transplantation 
(SCT). Heart failure was induced using 170 mg/kg/d of isoproterenol subcutaneously injection in 4 consecutive days. The 
failure confirmed by the rat cardiac echocardiography on day 28. In SCT group, 3×106 cells in 150 µl of culture media were 
transplanted to the myocardium. At the end, echocardiographic and hemodynamic parameters together with histological 
evaluation were done.
Results: Echocardiography results showed that cardiac ejection fraction in HF group increased from 58/73 ± 9% to 81/25 
± 6/05% in SCT group (p value < 0.001). Fraction shortening in HF group was increased from 27/53 ± 8/58% into 45/55 ± 
6/91% in SCT group (p value < 0.001). Furthermore, hAMSCs therapy significantly improved mean diastolic blood pressure, 
mean arterial pressure, left ventricular systolic pressure, rate pressure product, and left ventricular end-diastolic pressure 
compared to those in the HF group, with the values reaching the normal levels in the control group. A marked reduction in 
fibrosis tissue was also found in the SCT group (p value < 0.001) compared with the animals in the HF group.
Conclusion: The transplantation of hAMSCs in rats with heart failure not only decreased the level of fibrosis but also 
conferred significant improvement in heart performance in terms of echocardiographic and hemodynamic parameters. 
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Introduction
Heart failure (HF) is a common and highly important 
health problem throughout the world. According to statistics, 
it is estimated that more than 5.2 million Americans have HF 
and approximately 10% to 13% of deaths are caused by HF.1 
Mesenchymal stem cells (MSCs) are used in clinical 
practice for various therapeutic purposes, and their safety 
and possibility for use in cell therapy in the heart have been 
proven.2 The most common source of MSCs used in clinical 
practice is bone-marrow MSCs.3 Among such sources, 
human amniotic mesenchymal stromal cells (hAMSCs) 
have properties that are superior to those in other sources. 
The human amniotic membrane, which is an extraction 
source for MSCs, is readily available after each delivery 
and is usually discarded as medical waste. Its use does not 
pose risk to mother and baby, so there is no problem in its 
legal use. Unlike other human mesenchymal cells, hAMSCs 
have a high immunological tolerance and can be used as a 
valuable source of MSCs in transplantation and tissue repair.3 
Studies have shown that hAMSCs can differentiate both in 
vitro and in vivo in various cells such as cardiomyocytes.4 
Furthermore, it appears that as a result of their embryonic 
origin, the proliferation and differentiation capacity of these 
cells is greater than that of the other mesenchymal cells. 
According to the features listed, hAMSCs have a special 
place in regenerative medicine. The aim of this study was 
to investigate the functional and histological effects of 
hAMSCs transplantation following isoproterenol (ISO)-
induced global HF in male rats.
Methods
In this research, MSCs from the human amniotic membrane 
were isolated and then cultured based on enzymatic methods 
formerly described.5 In short, the amnion was mechanically 
separated from the chorine and cut into very small pieces. 
The amniotic crushed pieces were digested with 0.25% 
trypsin (Gibco, USA) and collagens 1 (0.75 mg/mL). The cell 
suspension was filtered through a 70-μm Falcon cell strainer 
(Falcon, USA). The collected cells were seeded in 25-cm2 
Cole flasks composed of low-glucose Dulbecco’s modified 
eagle’s medium (DMEM-LG; Gibco, USA) plus medium 
supplemented with 20% fetal bovine serum (FBS; Gibco, 
USA). Two days later, the culture medium was replaced 
for the first time and only the remaining cells adhered to 
the bottom of the flask. These cells were gradually spindle-
shaped and after 28 days, they reached 80% confluence and 
were passaged. The passages of the 3rd to 5th cells were 
used for transplantation in the cell-treated group. The pair of 
amniotic membrane used to isolate the MSCs was obtained 
from vaginal delivery.
The origin of the mesenchymal isolated cells was assessed 
using flow cytometry. For flow cytometry, the cell samples 
were prepared from passages 5. Initially, the cell suspension 
contained 103 cells/µL by trypsin. Thereafter, 50 µL of the 
cell suspension and 5 µL of specific antibody FITC or PE were 
mixed for 30 minutes at 4 °C in the dark. After fixation with 
4% paraformaldehyde solution, the samples were analyzed 
using a flow cytometer (Partec PAS III). The following 
antibodies were used: CD 34-FITC (BD Pharmingen; Clone: 
5E 10), CD 45-FITC, and CD 105-PE. 
For osteogenic differentiation, the isolated cells were 
cultured in the osteogenic induction medium containing 
DMEM high glucose, 10% FBS, 10-7 M of dexamethasone 
(Sigma), 10 mM of β-glycerophosphate (Merck, Darmstadt, 
Germany), and 0.5 mM of ascorbic acid 2-phosphate (Sigma) 
for 4 weeks and the media were changed every 3 days.6 
Alizarin red staining was used to evaluate the differentiation 
potential of the isolated osteocytic cells. For adipogenic 
differentiation, the cells were incubated with the adipogenic 
induction medium containing DMEM, 10% FBS,10-6 M of 
dexamethasone, 0.5 mM of 3-isobutyl-1-methylxanthine 
(Sigma), 200 µM of indomethacin (Sigma), and 10 µg/mL 
of insulin (Gibco) for 4 weeks and the media were changed 
every 3 days. Oil Red O staining was demonstrated in 
evaluating the adipogenic differentiation.7
In order to tracking the transplanted MSCs in myocardium, 
Chloromethylbenzamido-1, 1´-Dioctadecyl-3,3,3´3´-
Tetramethylindocarbocyanine Perchlorate (CM-DiI) was 
used as a marker. The stock solution of lipophilic tracers 
CM-DiI (Cell Tracker CM-DiI; Invitrogen, USA) was 
prepared according to the manufacturer’s instructions. 
The final concentration of CM-DiI stock was made up to a 
concentration of 1 mg/mL in dimethyl sulfoxide (DMSO; 
Sigma). Immediately before labeling, the stock solution was 
diluted with Dulbecco’s phosphate-buffered saline (D-PBS).
The  hAMSCs  were  harvested  28  days  after  the  last 
ISO  injection  ,and  MSCs  staining  at-1  µM)  molecular 
weight  CM-DiI  is  close  to  ;1000  therefore  1  ,µM~1 µg/
mL) concentrations was performed for 5 minutes at 37 °C 
and finally for 15 minutes at 4 °C, with occasional mixing 
to improve staining levels according to the manufacturer’s 
standard protocol.8 After being labeled, the MSCs were 
washed with PBS and resuspended in 150 µL of a fresh 
medium and injected into the myocardium. In this study, 28 
days after the transplantation of hAMSCs, the animals in 
the SCT group (n = 7) were sacrificed, and paraffin blocks 
were prepared from the heart. Then, slides with a thickness 
of 5 µm were prepared and analyzed using a microscope 
(Olympus, Tokyo, Japan).
The protocol was approved by the institutional Care and 
Use Committee of Iran University of Medical Sciences 
(Tehran, Iran). The experiments were performed on 35 male 
Wistar rats (180-200 g), which were housed in controlled 
environment conditions (22 ± 2 °C; light – dark cycle 
7 am – 7 pm). The rats were allowed to access water and 
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standard laboratory food ad libitum. ISO-induced global HF 
was effected as described in a previous study.9 In summary, 
ISO (170 mg/kg dissolved in 0.5 mL of saline, Sigma, 
USA) was subcutaneously injected into the rats every 
day for 4 sequential days. Twenty-eight days after the last 
injection of ISO, the establishment of HF was confirmed 
with echocardiography through ejection fraction percentage 
(EF, %) measurement (EF < 70%), and the animals with 
EF > 70% were not used in the intervention groups. The 
animals were divided into 5 groups (n = 7, each group). Four 
weeks post ISO injection, failure confirmation was done by 
echocardiography. The hAMSCs (3 × 106) were dissolved in 
150 µL of a culture medium and injected into 4 points along 
the left anterior descending artery (LAD) path (stem cell 
transplantation [SCT] group). The culture medium without 
hAMSCs in the same volume was also injected accordingly 
(CM group). Four points along the LAD path were also 
punctured post failure induction without cell injection 
(sham group). The control (con) group, animals received no 
intervention and in a group called heart failure (HF) group 
were injected only ISO and surgical intervention was not 
performed. In all the groups studied (n = 7 from each group), 
the rats were evaluated at the beginning of the study and a 
similar echocardiogram was performed again 4 and 8 weeks 
after the last ISO injection. The echocardiograms were done 
following mild anesthesia (induced with ketamine [80 mg/
kg] and xylazine [8 mg/kg], intraperitoneally) and carried 
out under continuous electrocardiogram (ECG) monitoring 
with an echocardiographic system equipped with a 6–12 
MHz linear transducer (GE Voluson 730 Pro, Kretztechnik 
Company, Austria).  The echocardiographic investigations 
were carried out by a researcher who was unaware of the 
treatment protocol. First, 2-dimensional (B-mode) images 
were obtained in the middle section of the parasternal 
short-axis view of the left ventricle (LV). At the level of the 
papillary muscles, M-mode tracings from the parasternal 
long-axis view were used to measure the echocardiographic 
parameters: LV end-diastolic dimension (LVDd, cm), LV 
end-systolic dimension ([LVDs], cm), intraventricular 
septal width in diastole ([IVSd], cm), intraventricular septal 
width in systole (IVSs, cm), LV end-diastolic posterior wall 
thickness (LVPWTd, cm), and LV end-systolic posterior wall 
thickness (LVPWTs, cm). Fractional shortening (FS, %) was 
calculated as (LVDd-LVDs)/LVDd] × 100. Additionally, EF 
(%) was calculated as [(LVDd
3-LVDs
3)/LVDd
3] × 100. All the 
parameters were measured from at least 3 successive cardiac 
cycles and averaged.
The hemodynamic parameters in all the groups studied (n 
= 7 from each group) were evaluated at 8 weeks after the 
last ISO injection, following echocardiography. The rats 
were anesthetized with thiopental (60 mg/kg) and under 
continuous ECG monitoring, a polyethylene tube (PE50, 0.58 
mm ID × 0.96 mm OD, Portex, England) filled with heparin 
saline (500 U/mL) was inserted into the carotid artery. This 
catheter was attached to the Power Lab data acquisition 
system via a pressure transducer (AD Instrument Pty Ltd, 
Mountain View, CA, USA) and thereby systolic blood 
pressure (mmHg) and diastolic blood pressure (mmHg) were 
constantly monitored and recorded on a computer throughout 
the research. Thereafter, the catheter was carefully pushed 
forward into the LV. LV systolic pressure (LVSP, mmHg), 
LV end-diastolic pressure (LVEDP, mmHg), maximum rate 
of LV pressure rise (+dP/dt, mmHg/s; contractility), and 
maximum rate of LV pressure decline (-dP/dt, mmHg/s, 
relaxation) were monitored and recorded. Also, rate pressure 
product (beats × mmHg/min) was obtained by multiplying 
heart rate in LV developed pressure (LVDP). LVDP was 
the result of the pressure difference of the systolic and 
diastolic pressures of the LV. Upon the completion of the 
hemodynamic evaluation, the animals were sacrificed and 
their heart was immediately removed by cutting the large 
blood vessels connected to it.
For histological studies, 8 weeks after the last ISO injection, 
at the end of the hemodynamic parameter measurements, the 
rats (n = 7 from each group) were sacrificed and cut into 3 
transverse segments parallel to the atrioventricular groove. 
After the preparation of the paraffin blocks of the heart tissue, 
slices were prepared with a thickness of 5 µm. Masson’s 
trichrome and hematoxylin and eosin (H & E) staining were 
performed to study the histological changes. 
Masson’s trichrome staining was conducted to evaluate 
interstitial fibrosis in the myocardium. The surface area of 
the fibrosis of the cardiac muscle was calculated as follows: 
the transverse sections were randomly obtained from 2 levels 
(basal and apical), and 10 randomly chosen fields for each 
section (n = 20 per animal) were analyzed. Then, for each 
field at 200 × magnification, photography was done using a 
digital photography camera and the images were stored in 
a computer. Image J, version 1.48, (US National Institutes 
of Health, Bethesda, MD, USA) was used to measure the 
amount of fibrosis in each section. The percentage of fibrotic 
tissue infiltration in the LV was calculated as follows10: 
(Fibrotic tissue area)/(fibrotic tissue area + myocyte area) × 
100%. 
The statistical analyses were performed with Statistical 
Package for the Social Sciences (SPSS) (version 21.0; SPSS, 
Chicago, IL). The data are presented as means ± SDs .The 
independent  sample  t-test was used for the comparison of 
the echocardiographic indices between the control and HF 
groups to confirm HF. The one-way ANOVA and Bonferroni 
post hoc test were utilized to compare the echocardiographic 
and hemodynamic indices between the groups. A p value < 
0.05 was considered statistically significant.
Results
The rats were carefully monitored throughout the study 
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period in terms of the mortality rate. Fifty-one rats were used 
at the beginning of the study. Of these rats, 7 were randomly 
selected as the control group (intact animals). Twelve out 
of the remaining 44 animals died in the first 24 hours post 
ISO injection. Four rats also died in the second post ISO 
injection. Finally, the remaining 28 rats were randomly 
placed in equally numbered groups. No death was found in 
the control group during the investigation.
Four weeks after transplantation, the cells labeled with 
a fluorescent dye (CM-DiI) showed the existence of 
transplanted hAMSCs in the myocardium of the animals 
from the SCT group (Figure 1). 
Figure 1.  Two fluorescence microscopy views of a region in the myocardial.
A) Chloromethylbenzamido-1,1´-Dioctadecyl-3,3,3´3´Tetramethylindocarb
ocyanine Perchlorate (CM-DiI) labeled mesenchymal stem cells (MSCs) 
can be seen as bright red color spots in the myocardium. B) View from the 
same spot in the myocardium that did not receive stem cell transplant. 
Magnification × 200, Scale bar = 100 nm
The flow cytometry results showed that the isolated cells 
expressed the MSC marker CD105 but did not express 
the hematopoietic progenitor marker CD34 and the pan-
leukocyte marker CD 45 (Figure 2).
Three days after cell isolation, the mesenchymal cells 
were cultured in the adipogenic induction medium, and lipid 
droplets were observed in some cells. With time, these droplets 
gradually increased in cells and after 21 days of culture, the 
lipid droplets were observed to be reddish in color with Oil 
Red O staining (Figure 3A). After 21 days of culture, with 
alizarin red staining, cell mass in terms of mineral matrix 
secretion was evaluated and the result showed red cell mass, 
which implied that the test was positive (Figure 3B).
Four weeks after the last ISO injection, LVDs (p value < 
0.001), LVDd (p value = 0.009), and IVSs (p value = 0.012) 
were all increased, while EF (p value < 0.001) and FS (p 
value < 0.001) decreased compared with the values in the 
control animals. This was indicative of HF development. 
Eight weeks after the last ISO injection, LVDs (df: 33; F = 
21.10; p value < 0.001) and LVDd (df: 33; F = 15.26; p value 
< 0.001) showed changes in all different animals. These 
parameters were significantly higher in the HF group than 
in the control group (p  value  .(0.001 > Although hAMSCs 
transplantation decreased LVDs (p value = (0.078 and LVDd 
(p value = 0.459) compared to the values in the HF group, 
the effect was not statistically significant. The transplantation 
of hAMSCs in the SCT group failed to bring LVDs (p value 
< 0.001) and LVDd (p value = 0.001) to the values in the 
control group (Figure 4A & Figure 4B).
Eight weeks’ follow-up showed a significant difference in 
IVSs (df: 33; F = 7.86; p value < 0.001) and IVSd (df: 33; 
F = 2.7; p value = 0.041) among the studied groups. IVSs (p 
value = 0.001) and IVSd (p value = 0.049) in the HF group 
were significantly lower than those in the control animals. 
The transplantation of hAMSCs increased IVSs diameter 
compared to that in the HF group (p value < 0.001). There 
was no significant difference between the SCT group and the 
control group (p value = 0.647). However, this therapeutic 
strategy did not affect IVSd (p value = 0.015) (Figure 4C & 
Figure 4D).
LVPWs was statistically different between the groups (df: 
33; F = 3.50; p value = 0.014), but LVPWd did not change 
(df: 33; F = 1.0; p value = 0.422). LVPWs was thicker in 
the SCT group than in the HF group (p value = 0.024) and 
the sham group (p value = 0.035) (Figure 4E & Figure 4F). 
Furthermore, EF (df: 33; F = 8.68; p value < 0.001) and 
FS (df: 33; F = 9.68; p value < 0.001) were significantly 
decreased 8 weeks after HF induction. However, hAMSCs 
transplantation provoked a significant increase in EF (p 
value < 0.001) and FS (p value < 0.001) in comparison with 
those in the HF group (Figure 4G & Figure 4H). There was 
no significant difference between the SCT group and the 
control group. (p value = 1.000) (Table 1). 
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Figure 2. Immunophenotypic characterization of the amniotic membrane-derived stem cells .These cells expressed mesenchymal stem cell marker CD105 
(A), whereas they were negative for CD34 (B) and CD 45 (C). 
Figure 3. The microscopic images differentiation human amniotic membrane-derived mesenchymal cell into osteocytes and adipocytes. 
A) Osteogenic differentiation was evidenced by the formation of extracellular calcium deposits (alizarin red staining positive) which can be seen as red 
regions. B) Adipogenic differentiation was confirmed by the formation of intracellular lipid droplet (Oil Red O staining positive) these droplets can be seen 
as red regions. 
Magnification × 200
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Figure 4. Effects of human amniotic mesenchymal stromal cells (hAMSCs) transplantation on left ventricular (LV) echocardiographic parameters in the 
studied animals (each group n=7). A) LVDs (Left ventricular end-systolic dimension). B) LVDd (LV end-diastolic dimension). C) IVSs (Intraventricular 
septal width in systole). D) IVSd (Intraventricular septal width in diastole). E) LVPWTs (LV end-systolic posterior wall thickness). F) LVPWTd (LV end-
diastolic posterior wall thickness). G) EF (Ejection fraction). H) FS (Fractional shortening). Con, control group; HF 8 weeks, rats with heart failure in eight 
weeks after injection of isoproterenol.
Sham, Sham operating group; CM, Culture media group; SCT, Stem cell transplantation group. 
Data are presented as means±SD
*: significant difference vs. control, *p value < 0.05, **p value < 0.001
†: significant difference vs. SCT, † p value < 0.05, ††: p value < 0.001
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 Table 1. Echocardiographic findings in the experimental groups*
Studied Groups
P value
Control HF 4 weeks HF 8 weeks Sham Culture Media SCT
LVDs (cm) 0.26±0.06 0.40±0.07 0.42±0.03 0.40±0.04 0.43±0.05 0.37±0.05 < 0.001
LVDd (cm) 0.45±0.08 0.59±0.11 0.62±0.04 0.63±0.10 0.65±0.03 0.57±0.05 < 0.001
IVSs (cm) 0.27±0.04 0.21±0.04 0.20±0.03 0.22±0.06 0.22±0.04 0.27±0.04 < 0.001
IVSd (cm) 0.21±0.04 0.16±0.04 0.16±0.04 0.16±0.05 0.16±0.01 0.18±0.02    0.041
LVPWs (cm) 0.27±0.09 0.21±0.04 0.22±0.05 0.23±0.04 0.23±0.06 0.29±0.04    0.014
LVPWd (cm) 0.19±0.07 0.19±0.04 0.23±0.05 0.23±0.07 0.22±0.05 0.21±0.03    0.422
EF (%) 79.67±5.90 65.73±9.51 58.73±14.85 70.63±8.25 62.25±16.79 81.45±6.06 < 0.001
FS (%) 41.94±4.41 31.87±6.55 27.53±8.58 36.00±6.76 31.63±12.22 45.55±6.91 < 0.001
*Data are presented as mean±SD
HF 4 weeks, Rats with heart failure in four weeks after injection of isoproterenol; HF 8 weeks, Rats with heart failure in eight weeks after injection of 
isoproterenol;
SCT, Stem cell transplantation; LVDs, Left ventricular internal dimension in systole; LVDd, Left interventricular internal dimension in diastole; IVSs, In-
terventricular septal thickness in systole; IVSd, Interventricular septal thickness in diastole; LVPWs, Left ventricular posterior wall in systole; LVPWd, Left 
ventricular posterior wall in diastole; EF, Ejection fraction; FS, Fraction shortening.
Table 2. Hemodynamic assessment in the experimental groups*
Studied Groups
P value
Control HF8  weeks Sham Culture Media SCT
HR (beat/min) 379.35±14.53 382.34±27.05 360.29±22.20 365.51±27.75 378.07±37.52     0.580
SBP (mmHg) 130.02±12.98 119.76±10.94 112.94±15.20 109.02±17.10 126.77±10.09     0.074
DBP (mmHg) 110.76±7.66 88.26±10.13 94.18±12.70 91.71±14.02 101.33±13.67     0.031
MAP (mmHg) 117.16±9.26 98.70±9.58 100.39±13.43 97.47±14.67 109.87±11.94     0.045
Max dP/dt (mmHg/s) 4517.50±377.78 3046.60±215.62 3016.00±344.09 2938.60±278.91 3637.20±181.84 < 0.001
Min dP/dt (mmHg/s) -3331.67±368.86 -2262.00±256.68 -2128.20±143.60 -2196.80±112.13 -2541.72±374.79 < 0.001
LVSP mmHg 8.36±2.49 28.88±10.43 29.39±6.59 28.29±6.73 14.40±10.98      0.003
LVEDP mmHg 115.91±17.94 84.09±10.82 88.69±8.52 91.84±11.41 109.42±16.65 < 0.001
RPP (beat/min × mmHg) 41671.20±7264.27 20975.00±5639.48 21413.67±3449.53 21231.40±3163.38 38270.17±8303.96 < 0.001
*Data are presented as mean±SD
HF 8 weeks, Rats with heart failure in eight weeks after injection of isoproterenol.
HF, Heart failure; SCT, Stem cell transplantation; HR, Heart rate ; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; MAP, Mean arterial pressure; 
LVSP, Left ventricular systolic pressure; LVEDP, Left ventricular end-diastolic pressure; Max dP/dt, Maximum rate of left ventricular pressure rise; Min dP/
dt, Maximum rate of left ventricular pressure decline; RPP, Rate pressure product 
Our results did not show significant differences in heart 
rate (df: 33; F = 0.72; p value = 0.580) and systolic blood 
pressure (df: 33; F =  1.46; p value = 0.074) between the 
groups, while mean diastolic blood pressure  (df: 33; F = 
3.21; p value = 0.031), mean arterial pressure (df: 33; F = 
2.88; p value = 0.045), max dP/dt (df: 33; F = 29.17; p value 
< 0.001), min dP/dt (df: 33; F = 17.87; p value < 0.001), 
LVSP (df: 33; F = 5.60; p value = 0.003), LVEDP (df: 33; F 
= 7.61; p value < 0.001), and rate pressure product (df: 33; F 
16.07; p value < 0.001) were strikingly different between the 
studied animals (Table 2).
As was expected, HF induction caused a significant 
decrease in diastolic blood pressure (p value = 0.044), mean 
arterial pressure (p value = 0.046), LVSP (p value = 0.011), 
max dP/dt (p value < 0.001), and rate pressure product (p 
value < 0.001) but provoked a marked increase in LVEDP (p 
value = 0.007) and min dP/dt (p value < 0.001) compared to 
the same values in the control animals. The transplantation 
of hAMSCs reversed these complications. There was no 
significant difference between the SCT group and the control 
group in diastolic blood pressure (p value = 0.180), mean 
arterial pressure (p value = 0.288), LVSP (p value = 0.106), 
rate pressure product (p value = 0.501), and LVEDP (p value 
= 0.982) (Figure 5). However, mean max dP/dt (p value = 
0.001) and min dP/dt (p value = 0.001) were significantly 
higher than those in the control group.
Our quantitative analysis showed that fibrosis tissue 
percentage significantly increased in the HF group compared 
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with that in the control group (19.56 ± 2.76% vs. 4.85 ± 0.43%; 
p value < 0.001). The implantation of hAMSCs significantly 
reduced fibrosis formation (Figure 6). However, fibrosis 
percentage was significantly higher in the SCT group than 
in the control animals (12.07 ± 1.12% vs. 4.85 ± 0.43%; p 
value < 0.001) (Figure 7). In addition, H&E staining showed 
that the myocardial tissues changed and lost their integrity 
and order after HF induction. The space between the cells 
and cardiomyocytes was also increased, which made them 
lose their natural structure. In the SCT group, there was 
repair of the damage, approximating the myocardial tissue 
to that of the healthy rats. Also, the order and integrity of 
cardiomyocytes were re-established (Figure 8).
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Figure 5.  Effects of human amniotic mesenchymal stromal cells (hAMSCs) transplantation on left ventricular (LV) hemodynamic parameters in the studied 
animals (each group n = 7).
A) SBP (systolic blood pressure), B) DBP (diastolic blood pressure), C) MAP (mean arterial pressure), D) LVSP (left ventricular systolic pressure), E) 
LVEDP (left ventricular end-diastolic pressure), F) + dP/dt (maximum rate of left ventricular pressure rise), G) -dP/dt (Maximum rate of left ventricular 
pressure decline), and H) RPP (rate pressure product).
Control, control group; HF, Heart failure group; Sham, Sham operating group; CM, Culture media group; SCT, Stem cell transplantation group 
Data are presented as means±SD.
*significant difference vs. control, *p value < 0.05, **p value < 0.001
†significant difference vs. SCT, †p value < 0.05, ††p value < 0.001
Figure 6. Cross sections of left ventricular myocardial tissue stained with trichrome mission. In these images fibrous areas appear turquoise blue in color.
A) Control group, B) Heart failure group, C) Culture media group, D) Sham operating group, and E) Stem cell transplantation group
Magnification × 200
Scale bar = 100 nm
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Figure 7. Effects of human amniotic mesenchymal stromal cells (hAMSCs) transplantation on myocardial fibrosis fraction in the studied animals (each 
group n = 7). 
Control, control group; HF, Heart failure group; Sham, Sham operating group; CM, Culture media group; SCT, Stem cell transplantation group 
*significant difference vs. control, *p value < 0.05, **p value < 0.001
†significant difference vs. SCT, †p value < 0.05, ††p value < 0.001
Figure 8. Representative hematoxylin-eosin stained myocardial sections in the studied animals
Great flash shows cardiomyocytes with normal nucleus and small arrow shows cardiomyocytes with nucleus pyknotic.
A) Control group, B) Heart failure group, C) Culture media group, D) Sham operating group, and E) Stem cell transplantation group
Magnification × 400 
Scale bar = 100 nm
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Discussion
In the near future, stem cell therapy may become an 
alternative treatment for cardiac failure. There are various 
methods for creating models of HF in laboratory animals.11 
ISO-induced HF is a standard method in which extensive 
myocardial damage gradually progresses (it is, therefore, a 
time-dependent process),9 while the vascular system remains 
intact in the heart. It is almost like the natural process that 
occurs in vivo during HF.12 In the present study, we used this 
model of HF induced by ISO.
Our results confirmed the findings of previous studies 
insofar as-in comparison with the control group-HF 
increased heart dimensions (increase in LVDs and LVDd) and 
reduced heart function (decrease in EF).13 Increased LVEDP 
in the HF group may have been due to impaired LV pumping 
function and inadequate emptying, which then might have 
provoked ventricular dilation and blood retention. Our data 
analysis showed that hAMSCs transplantation decreased 
LVEDP. This suggests that cell therapy prevents ventricular 
dilation and collection of blood in the LV. Our evaluation of 
the hemodynamic parameters indicated changes in the index 
contraction and relaxation of the LV in HF. Indeed during HF, 
collagen due to increased levels of matrix metalloproteinases 
(MMPs) and interstitial fibrosis collagen with cross bridges 
are poorly made, which in turn may lead to ventricular 
dilation and myocardial dysfunction.14
In the cell-treated group, the heart dimensions were 
decreased, and EF and FS were significantly increased. 
These results chime in with those in a study by Li et al.9 
Studies have shown that MSCs transplantation can inhibit 
the expression of MMPs and collagen ,which is capable of 
reducing  the  dimensions  of  the  heart  and  causing  dilation. 
Similar  to  the  investigation  by  Li  et  al9,. we demonstrated 
that IVSs and IVSd were reduced in HF and improved with 
stem cell transplantation. The decrease in heart dimensions 
improved the function of the ventricles in smaller 
dimensions,15 like what which seen in the natural state and 
prevented the cardiomyocytes from stretching too much, 
thereby conferring better contractile power.16
In the present study, hemodynamic parameters were also 
measured to assess ventricular function.12 The ventricular 
remodeling that occurs during HF may cause cardiac 
dysfunction in both systole and diastole.9 A reduction 
in systolic blood pressure, diastolic blood pressure, and 
LVSP following HF induction can be caused by the death 
of cardiomyocytes, myocardial necrosis, and myocardial 
stunning. Increased systolic and diastolic pressures 
following hAMSCs transplantation may be partly due to the 
conversion of the transplanted MSCs into cardiomyocytes4 
and myocardial stem cells paracrine factors (such as 
hepatocyte growth factor) with trophic and cardioprotective 
properties.17, 18
The results of the current study showed the effect of 
hAMSCs transplantation on reducing the amount of fibrosis 
in the myocardium, as compared to other cells used in 
previous studies which are more. For example, in the 
study by Li et al.,9 the fibrosis content of the myocardium 
in rats with HF decreased from 11.3% to 9.8% after the 
transplantation of bone-marrow MSCs. In contrast in the 
present study, the extent of fibrosis in the myocardium 
of the rats with HF decreased from 19.5% to 12.0% after 
hAMSCs transplantation. In their study, Li et al.9 could not 
find evidence of the differentiation of bone-marrow-derived 
MSCs into cardiomyocytes. Therefore, a reduction in 
myocardial fibrosis can cause the release of MSCs paracrine 
factors. Studies have confirmed that hAMSCs could be 
transdifferentiated into cardiomyocytes in vitro and in vivo, 
without requiring any epigenetic factor or gene transfer.17 
Thus, it seems that part of the reduction in myocardial fibrosis 
and cardiac repair is related to the homing and differentiation 
of stem cells into cardiomyocytes.12, 19 It should also be 
noted that autocrine and paracrine products released by 
the transplanted cells are involved in reducing the damage 
caused by HF in the myocardium.20, 21 Accordingly, it seems 
that statistically the effect of hAMSCs on fibrous reduction 
is more than bone marrow-derived mesenchymal stem cells. 
Because hAMSCs act in both ways, they differentiate into 
cardiomyocytes and bring about the delivery of autocrine 
and paracrine factors.
Increased collagen content and fibrosis in the interstitial 
space have been seen in many cases of myocardial hypertrophy 
such as which occurs during HF, and they trigger a variety 
of changes in ventricular pressures.10, 22 Hence, it seems that 
one of the ways in which MSCs transplantation can improve 
cardiac function is by reducing myocardial fibrosis.
Lifestyle change, improved nutrition, and pharmacological 
therapy with medications such as ivabradine23 and LCZ69624 
have little effects on heart performance in cardiac failure 
states and can only slow its progression, without any 
compensatory influence on cell loss.25, 26 The transplantation 
of hAMSCs allows non-functional cardiomyocytes and scar 
tissues to be replaced with healthy cells with normal function 
and can revert the side effects of HF for good in comparison 
with transient palliative modalities.
Conclusion 
This study recorded significant improvement in cardiac 
function and reduction in cardiac fibrosis in the stem 
cell transplantation group when compared with the heart 
failure, sham and culture medium groups. The results of this 
study suggest that human amniotic mesenchymal stromal 
cell transplantation has cardioprotective effects on heart 
failure. Evidence for this cardioprotective effect comes 
from the results of echocardiographic studies, measurement 
of hemodynamic parameters, and histological findings. 
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Therefore, it seems that human amniotic mesenchymal 
stromal cell transplantation has the potential to be used for 
the treatment of heart failure.
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